Jump to ContentJump to Main Navigation

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

12 Issues per year


SCImago Journal Rank (SJR): 1.550
Source Normalized Impact per Paper (SNIP): 0.734

VolumeIssuePage

Issues

mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer

Matthias Kotzsch1 / Julia Dorn2 / Kristina Doetzer2 / Barbara Schmalfeldt2 / Janna Krol2 / Gustavo Baretton1 / Marion Kiechle2 / Manfred Schmitt2 / 2

1Institut für Pathologie, Technische Universität Dresden, D-01307 Dresden, Germany

2Klinische Forschergruppe der Frauenklinik, Technische Universität München, D-81675 München, Germany

Corresponding author

Citation Information: Biological Chemistry. Volume 392, Issue 11, Pages 1047–1051, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: 10.1515/BC.2011.166, August 2011

Publication History

Received:
2011-05-26
Accepted:
2011-08-11
Published Online:
2011-08-18

Abstract

High tumor tissue mRNA expression of the tumor biological factors uPAR, uPAR-del4/5, or rab31 is associated with shorter distant metastasis-free and overall survival in breast cancer patients. To evaluate whether these factors are also clinically relevant in ovarian cancer, we quantified the respective mRNA levels in primary tumor tissue of advanced ovarian cancer patients (n=103) and evaluated their association with clinicopathological parameters and patients’ prognosis. mRNA expression levels of all three markers did not show any significant association with overall or progression-free survival, demonstrating that these factors have no prognostic value in advanced ovarian cancer.

Keywords: ovarian cancer; prognosis; quantitative PCR; rab31; uPAR; uPAR-del4/5

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.